Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

1989 • 417 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

1993 • 354 citations

BILATERAL ADRENALECTOMY IN PROSTATIC CANCER

1945 • 345 citations

Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer

1992 • 206 citations

STEROIDS OF ADRENAL ORIGIN METABOLIZED BY HUMAN PROSTATIC TISSUE BOTH IN VIVO AND IN VITRO

1974 • 192 citations

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

1992 • 175 citations

Carcinoma of the prostate. Hormonal therapy

1987 • 103 citations

Cortisone Treatment in Advanced Carcinoma of the Prostate

1954 • 62 citations

Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic Cancer

1987 • 58 citations

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients

1988 • 36 citations

Prostate Specific Antigen for Assessing Response to Ketoconazole and Prednisone in Patients with Hormone Refractory Metastatic Prostate Cancer

1990 • 35 citations

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

1990 • 30 citations

Adrenal androgen blockade in relapsed prostate cancer

1985 • 27 citations

Pituitary Adrenal and Gonadal Endocrine Suppression for the Primary Treatment of Prostate Cancer

1990 • 13 citations

Hormonal Therapy in Metastatic Prostatic Cancer

1987 • 9 citations

Suppression of Plasma Androgen Levels with a Combination Therapy of Depot-Estrogen (Turisteron^R) and Dexamethasone^R in Patients with Prostatic Cancer

2009 • 4 citations